Effect of tirelizumab combined with chemotherapy on the efficacy and tumor markers of non-small cell lung cancer
Wang Wei
Zhang Zhenhua
Li Wenjuan
Abstract：Objective To investigate the efficacy of tirelizumab combined with chemotherapy and the effect of tumor markers on non-small cell lung cancer(NSCLC).Methods The clinical treatment status of the 70 NSCLC patients admitted to our hospital from January 2020 to March 2022 was retrospectively analyzed.According to different treatment method,they were divided into single group(35 cases receiving chemotherapy regimen)and combined group(35 cases receiving tirelizumab combined with chemotherapy regimen).Tumor markers[serum keratin 19 fragment antigen 21-1(CyFRA21-1),carbohydrate antigen 125(CA-125),carcinoembryonic antigen(CEA)],epidermal growth factor receptor(EGFR),transforming growth factor-β1(TGF-β1),cycde-2(COX-2)were compared between the two groups before and after treatment.Objective response rate(ORR),clinical control rate(DCR)and incidence of adverse reactions were compared between the two groups.Results Compared with the single group,the levels of CyFRA21-1,CA-125,CEA,EGFR,TGF-β1 and COX-2 in the combined group were decreased more significantly after treatment[(8.69±2.05)ng/L vs.(10.43±2.52)ng/L,(38.76±4.77)U/ml vs.(42.92±5.33)U/ml,(5.88±1.16)ng/L vs.(7.13±1.25)ng/L,(129.57±6.82)ng/ml vs.(135.52±7.54)ng/ml,(29.54±4.31)μg/L vs.(32.69±5.28)μg/L,(39.94±3.23)pg/ml vs.(44.78±5.63)pg/ml](t=3.169,3.441,4.337,3.462,2.734,4.411,P<0.05).ORR and DCR in combined group were 57.14%and 85.71%,respectively,significantly higher than 31.43%and 62.86%in single group(χ2 =4.690,4.786,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Addition of tirelizumab to chemotherapy regimen for NSCLC can effectively reduce tumor markers,inhibit the expression of EGFR,TGF-β1 and COX-2,improve tumor control rate,delay disease progression,and do not increase the toxic side effects.
Keywords：TirelizumabChemotherapyNon-small cell lung cancerTumor markersClinical curative effect
Publication Date：2023-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 650-653 )